Zweig-DiMenna Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Zweig-DiMenna Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-160,198	Closed	-$13.2M	–	153
2016 Q1	$13.2M	Buy	160,198 +70,198	+78%	+$5.71M	1.17%	30
2015 Q4	$9.43M	Sell	90,000 -206,065	-70%	-$21.5M	0.47%	74
2015 Q3	$31.2M	Buy	296,065 +243,565	+464%	+$32.5M	1.35%	17
2015 Q2	$7.18M	Sell	52,500 -67,000	-56%	-$8.3M	0.4%	71
2015 Q1	$14.9M	Sell	119,500 -115,587	-49%	-$12.2M	0.62%	65
2014 Q4	$21.3M	Buy	235,087 +178,349	+314%	+$14.8M	0.91%	37
2014 Q3	$4.09M	Sell	56,738 -87,937	-61%	-$5.78M	0.18%	118
2014 Q2	$9M	Buy	144,675 +15,000	+12%	+$906K	0.41%	77
2014 Q1	$8.85M	Sell	129,675 -476,174	-79%	-$35.1M	0.52%	67
2013 Q4	$42.6M	Buy	605,849 +36,245	+6%	+$2.46M	1.56%	12
2013 Q3	$41.1M	Buy	569,604 +113,912	+25%	+$7.57M	1.67%	7
2013 Q2	$25.4M	Buy	+455,692	New	+$28.4M	1.03%	21

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Zweig-DiMenna Associates's BMRN Position: Q2 2016 in Review

Zweig-DiMenna Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2016, closing a stake of 160,198 shares — an estimated $13.2M sold.

Zweig-DiMenna Associates first reported a position in BMRN in Q2 2013 and held it in 12 quarters. The position peaked at $42.6M in Q4 2013. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

Zweig-DiMenna Associates reported no remaining BioMarin Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Zweig-DiMenna Associates sold 160,198 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $13.2M.
Zweig-DiMenna Associates first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Zweig-DiMenna Associates's BioMarin Pharmaceuticals position peaked at $42.6M in Q4 2013.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2016, filed 8 Aug 2016.